AI-generated · cited to primary sources · not investment advice · How we research
Laurus Labs
Our verdict on Laurus Labs isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
EBITDA margins saw a massive expansion of 1,080 bps in H1 FY26 compared to H1 FY25, reaching 25.4%. (4 exceeded, 1 met across 5 tracked commitments)
“It will be closer to INR1,000 crores. We invested about INR480 crores in H1, and we expect to invest similar amount in H2 as well.”
The company confirmed that the dedicated CMO oral dosage capacity (FDF) has commenced operations as of the December quarter reporting. (1 met across 1 tracked commitment)
“I think our first goal is to reach 50%. It's not going to be there in the medium term, it is a long-term goal for us to get there.”
See the full cited Management analysis of Laurus Labs
How durable is the business?
The CDMO small molecule division is expanding rapidly, driven by high-value projects from Big Pharma and new manufacturing assets coming online. It recorded 49% growth for the full year FY25. (5 expanding across 1 engine)
“CDMO - Small molecules: 408 Cr; 23% share; Y-o-Y 2%”
Generic Finished Dosage Forms (FDF) showed steady growth, supported by new product launches in the US and expansion of manufacturing lines. (2 expanding)
“FDF: 1,582 [FY25] vs 1,414 [FY24] 12%... Recent US launches picking up pace following new contracting”
See the full cited Business Model analysis of Laurus Labs
Where does growth come from?
The CDMO business is showing powerful acceleration, with Q4 FY25 growth of 85% significantly outperforming the full-year growth of 42%. (5 accelerating across 5 signals)
“On the CDMO side, we continue to see strong interest in our integrated service offerings across various complex technology platforms. Our cumulative 9-month performance has been very healthy, clocking more than 50% growth.”
Expansion is on track with a steady timeline; groundbreaking for the Vizag fermentation facility is scheduled for June 2025 with a 2026 completion target. (3 steady, 1 new trend across 4 signals, 1 leading indicator)
“~ ₹ 3,900 Cr Total CAPEX FY22-26... >85% in Growth CAPEX”
See the full cited Future Growth analysis of Laurus Labs
What could break the thesis?
INTENSIFYING. While annual growth was strong (+42%), the 'lumpiness' is evident in the Bio segment of CDMO, which saw a 40% decline quarter-on-quarter in Q4 FY25. (5 intensifying, 3 high-severity)
“The overall CAPEX this year will be about Rs. 1,000 crores and FY'26 based on the current estimate, we do feel it will be over Rs. 1,000 crores next year also.”
The risk is easing as gross margins expanded significantly to 59.5% due to better product mix (CDMO) and raw material price improvements. (3 easing, 2 stable, 1 high-severity)
“Higher ARV volumes and strong offtake in select molecules within developed markets offsetting price pressure.”
See the full cited Risk analysis of Laurus Labs
Read the full thesis on Laurus Labs
Laurus Labs Investment Analysis: Evaluating Growth Levers and Strategic Risk in the Pharma Sector
27 Apr 2026Laurus Labs Investment Analysis: Evaluating Strategic Growth and Pharmaceutical Innovation
20 Apr 2026Laurus Labs vs Divi's Laboratories: A Strategic Deep Dive into India's Pharmaceutical Leaders
14 Apr 2026Laurus Labs: The CDMO Pivot Ready to Ignite India’s Pharma Sector
03 Apr 2026AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.